Dialysis Procedures Alter Metabolic Conditions
- PMID: 28554992
- PMCID: PMC5490527
- DOI: 10.3390/nu9060548
Dialysis Procedures Alter Metabolic Conditions
Abstract
A progressive chronic kidney disease results in retention of various substances that more or less contribute to dysfunction of various metabolic systems. The accumulated substances are denominated uremic toxins. Although many toxins remain undetected, numerous newly defined toxins participate in the disturbance of food breakdown. In addition, toxic effects may downregulate other pathways, resulting in a reduced ability of free fatty acid breakdown by lipoprotein lipase (LPL) and hepatic lipase (HL). Dialysis may even worsen metabolic functions. For LPL and HL, the use of heparin and low molecular weight heparin as anticoagulation during hemodialysis (HD) initiate a loss of these enzymes from their binding sites and degradation, causing a temporary dysregulation in triglyceride breakdown. This lack of function will cause retention of the triglyceride containing lipids for at least 8 h. In parallel, the breakdown into free fatty acids is limited, as is the energy supply by them. This is repeated thrice a week for a normal HD patient. In addition, dialysis will cause a loss of amino acids and disturb glucose metabolism depending on the dialysates used. The addition of glucose in the dialysate may support oxidation of carbohydrate and the retention of Amadori products and subsequent tissue alterations. To avoid these effects, it seems necessary to further study the effects of anticoagulation in HD, the extent of use of glucose in the dialysate, and the supplementation of amino acids.
Keywords: dialysis; glucose; glycation end products; hemodialysis; heparin; lipase; lipids; malnutrition; peritoneal dialysis.
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
Uremic toxins and lipases in haemodialysis: a process of repeated metabolic starvation.Toxins (Basel). 2014 Apr 30;6(5):1505-11. doi: 10.3390/toxins6051505. Toxins (Basel). 2014. PMID: 24784324 Free PMC article. Review.
-
Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism.J Clin Endocrinol Metab. 1978 Dec;47(6):1173-82. doi: 10.1210/jcem-47-6-1173. J Clin Endocrinol Metab. 1978. PMID: 400739
-
Disorders of protein and lipid metabolism associated with chronic renal failure and chronic dialysis.Ann Clin Lab Sci. 1981 Jul-Aug;11(4):350-60. Ann Clin Lab Sci. 1981. PMID: 7023349 Review.
-
Lipoprotein lipase disturbances induced by uremia and hemodialysis.Semin Dial. 2009 Jul-Aug;22(4):442-4. doi: 10.1111/j.1525-139X.2009.00597.x. Semin Dial. 2009. PMID: 19708998 Review.
-
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.Clin Pharmacol Ther. 2003 Sep;74(3):236-44. doi: 10.1016/S0009-9236(03)00170-X. Clin Pharmacol Ther. 2003. PMID: 12966367 Clinical Trial.
Cited by
-
Intradialytic Nutrition and Hemodialysis Prescriptions: A Personalized Stepwise Approach.Nutrients. 2020 Mar 16;12(3):785. doi: 10.3390/nu12030785. Nutrients. 2020. PMID: 32188148 Free PMC article. Review.
-
Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohorts.Metabolomics. 2025 Jun 26;21(4):90. doi: 10.1007/s11306-025-02291-7. Metabolomics. 2025. PMID: 40569531 Free PMC article.
-
Blood Fatty Acid Status and Clinical Outcomes in Dialysis Patients: A Systematic Review.Nutrients. 2018 Sep 21;10(10):1353. doi: 10.3390/nu10101353. Nutrients. 2018. PMID: 30248953 Free PMC article.
-
Impact of Acetate versus Citrate Dialysates on Intermediary Metabolism-A Targeted Metabolomics Approach.Int J Mol Sci. 2022 Oct 2;23(19):11693. doi: 10.3390/ijms231911693. Int J Mol Sci. 2022. PMID: 36232995 Free PMC article.
-
Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity.World J Nephrol. 2022 Mar 25;11(2):39-57. doi: 10.5527/wjn.v11.i2.39. World J Nephrol. 2022. PMID: 35433339 Free PMC article. Review.
References
-
- Vanholder R., Argiles A., Baurmeister U., Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., Descamps-Latscha B., Henle T., et al. Uremic toxicity: Present state of the art. Int. J. Artif. Organs. 2001;24:695–725. - PubMed
-
- Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., Clark W., Cohen G., De Deyn P.P., Deppisch R., et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934–1943. doi: 10.1046/j.1523-1755.2003.00924.x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical